To determine the effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration (nAMD) in routine clinical practice.
In this retrospective case series, eyes initiating treatment for nAMD at an academic medical centre from 2011–2019 were included. Exclusion criteria included previous intravitreal anti-VEGF injections, prior non-cataract intraocular surgery, <1 year of treatment, and not starting on monthly bevacizumab therapy. Of 895 eligible eyes, 548 were excluded, yielding 347 eyes in the study population.
These eyes were treated for nAMD under the bevacizumab step therapy protocol with an option to switch to another agent in the event of predefined treatment failure. Treatment failure was defined as losing 15 or more Early Treatment Diabetic Retinopathy Study letters or switching to an alternative anti-VEGF agent. Eyes that did not meet these criteria were deemed treatment successes. Annual change in mean VA from baseline (ΔVA) was the primary outcome. Secondary outcomes included treatment success rate, medication switch rate, and post-switch ΔVA.
After 1 year, mean ΔVA was +8.4 letters (95% CI: +6.1 to +10.6 letters). 86% had treatment success, and 6% of eyes had switched to aflibercept. In years 2–7, ΔVA ranged from +7.0 to −0.7 letters, and treatment success rates ranged from 68 to 82%. 11% (n = 38) of eyes were switched to aflibercept. The post-switch ΔVA in these eyes was −7.1 letters (95% CI: −13.3 to −0.1) after a mean of 17.7 ± 12.6 injections over an average of 2.7 ± 2.0 years.
A bevacizumab step therapy protocol in routine clinical practice is effective for long-term treatment of nAMD.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The datasets analysed during the current study are not publicly available due to use of protected health information but are available from the corresponding author on reasonable request.
Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl J Med. 2004;351:2805–16.
Stone TW, ed. ASRS 2018 Preferences and Trends Membership Survey. Chicago, IL: American Society of Retina Specialists; 2018.
CATT Research Group, Martin DF, Maguire MG, Ying G-S, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl J Med. 2011;364:1897–908.
Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, Fine SL, Ying G-S, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258–67.
Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71.
Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300–9.
Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122:146–52.
Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.
Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. 2012;153:468–73.e1.
Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99:141–6.
Jiang S, Park C, Barner JC. Ranibizumab for age‐related macular degeneration: a meta‐analysis of dose effects and comparison with no anti‐VEGF treatment and bevacizumab. J Clin Pharm Ther. 2014;39:234–9.
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.
Patel S. Medicare spending on anti-vascular endothelial growth factor medications. Ophthalmol Retin. 2018;2:785–91.
Where the newest anti-VEGF agent fits in the exudative-disease toolbox: Retina Specialist; 2019 Available from: https://www.retina-specialist.com/article/where-the-newest-antivegf-agent-fits-in-the-exudativedisease-toolbox.
Berkowitz ST, Sternberg P, Feng X, Chen Q, Patel S. Analysis of anti–vascular endothelial growth factor injection claims data in US medicare part B beneficiaries from 2012 to 2015. JAMA Ophthalmol. 2019;137:921–8.
Rosenfeld PJ, Windsor MA, Feuer WJ, Sun SJ, Frick KD, Swanson EA, et al. Estimating medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration. Am J Ophthalmol. 2018;191:135–9.
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology. 2017;124:352–8.
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J. Switching to less expensive blindness drug could save Medicare Part B $18 billion over a ten-year period. Health Aff. 2014;33:931–9.
Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs CMS.gov: Centers for Medicare & Medicaid Services; 2018 Available from: https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-and-step-therapy-part-b-drugs.
New Step Therapy Policy Threatens Medicare Advantage Patients’ Timely Access to Sight-Saving Treatments [press release]. American Academy of Ophthalmology 2019.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1432–44.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1419–31.
Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30:1046–50.
Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181–92.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, et al. Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: data from the fight retinal blindness! registry. Ophthalmology. 2020;127:369–76.
Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83.
Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Maguire MG, Martin DF, Ying G-S, Jaffe GJ, Daniel E, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123:1751–61.
Gillies MC, Campain A, Barthelmes D, Simpson Judy M, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122:1837–45.
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.
Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retin. 2017;1:314–21.
Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, et al. Management and outcomes for neovascular age-related macular degeneration: analysis of United States Electronic Health Records. Ophthalmology 2020;127:1179–88.
CMS Office of Enterprise Data and Analytics. Medicare Part B Drug Spending Dashboard CMS.gov: Centers for Medicare & Medicaid Services; Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartB.
Goldberg RA, Flynn HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153:204–8.
VanderBeek BL, Bonaffini SG, Ma L. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol. 2015;133:1159–64.
Yu JH, Gallemore E, Kim JK, Patel R, Calderon J, Gallemore RP. Silicone oil droplets following intravitreal bevacizumab injections. Am J Ophthalmol Case Rep. 2018;10:142–4.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351–9.
Glasser DB, Parikh R, Lum F, Williams GA. Intravitreal anti-vascular endothelial growth factor cost savings achievable with increased bevacizumab reimbursement and use [published online ahead of print June 13, 2020]. Ophthalmology.
Christoforidis JB, Briley K, Binzel K, Bhatia P, Wei L, Kumar K, et al. Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model. Invest Ophthalmol Vis Sci. 2017;58:5636–45.
The study was supported in part by a Research to Prevent Blindness unrestricted grant to the Vanderbilt Eye Institute. The sponsor or funding organization had no role in the design or conduct of this research
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Siktberg, J., Kim, S.J., Sternberg, P. et al. Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. Eye (2022). https://doi.org/10.1038/s41433-022-02253-6